Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
Int J Immunopathol Pharmacol
; 27(4): 653-9, 2014.
Article
em En
| MEDLINE
| ID: mdl-25572747
ABSTRACT
Hereditary angioedema type I (HAE-C1-INH) is an inherited disorder characterized by repeated severe angioedema attacks mostly triggered by traumas, emotional stress, increased estrogen levels or surgical procedures, in particular, odontostomatological interventions. Icatibant, a bradykinin B2 receptor antagonist, has been approved for treatment of HAE attacks. In this paper we describe the off label administration of icatibant as short-term prophylaxis of dental extraction in a patient with HAE with the aim of preventing perioperative angioedema attacks. The drug showed an effective and safe profile. Thus, a short-term prophylaxis of angioedema attacks in patients with HAE may be arranged on a multidisciplinary basis, according to the clinical history of each single patients.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bradicinina
/
Angioedemas Hereditários
/
Uso Off-Label
/
Antagonistas de Receptor B2 da Bradicinina
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Int J Immunopathol Pharmacol
Ano de publicação:
2014
Tipo de documento:
Article